Skip to main content

Table 4 Odds ratios for the morbidity of MACCE

From: Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Variable OR 95 % CI P
Male 0.784 0.454–1.356 0.384
Age 1.017 0.994–1.041 0.155
ACS 1.024 0.806–1.300 0.848
Diabetes 2.028 1.298–3.169 0.002
Creatinine 0.991 0.977–1.005 0.206
Prior PCI 1.424 0.821–2.471 0.208
Prior myocardial infarction 1.126 00619–2.047 0.697
NYHA functional classification 1.035 0.663–1.614 0.881
  1. ACS Acute coronary syndrome. P < 0.05 was considered to indicate statistical significance